News articles about Merus (NASDAQ:MRUS) have been trending somewhat positive this week, according to Accern. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merus earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.5720624271849 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of research firms have recently weighed in on MRUS. BidaskClub raised Merus from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 30th. Zacks Investment Research raised Merus from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Wedbush reissued an “outperform” rating and set a $32.00 price objective on shares of Merus in a research note on Friday, January 12th. Finally, Royal Bank of Canada lowered Merus from an “outperform” rating to a “sector perform” rating and set a $28.00 price objective for the company. in a research note on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $30.25.

How to Become a New Pot Stock Millionaire

Shares of Merus (NASDAQ:MRUS) opened at $19.73 on Wednesday. Merus has a 52 week low of $13.23 and a 52 week high of $30.78. The company has a market capitalization of $385.31, a price-to-earnings ratio of -3.60 and a beta of 0.09.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at

Merus Company Profile

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Insider Buying and Selling by Quarter for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with's FREE daily email newsletter.